PBMs, insurers strike deals for Hep C drugs

Catamaran is the latest PBM to cut a deal for lower-priced hepatitis C treatments for its customers. At the beginning of February, Catamaran added Gilead Sciences' hepatitis C treatments, Harvoni and Sovaldi, to its national and value formularies, making these drug therapies the exclusive options for patients with hepatitis C. Catamaran’s decision came a month after CVS/Caremark struck a similar deal with Gilead Sciences to add Harvoni and Sovaldi to its formulary as exclusive options for patients with hepatitis C. More

BLOG

Hepatitis C market competition arrives for 2015

There is plenty of activity already in the hepatitis C market as competition has arrived for 2015, including CVS Health versus Express Scripts and Gilead Sciences versus AbbVie, over FDA-approved hepatitis C treatments. More

EDITOR'S CHOICE

PCORI approves funding for hepatitis C research

The Patient-Centered Outcomes Research Institute recently approved funding for up to four large studies comparing different approaches to treating hepatitis C. The institute also approved funding for phase II of National Patient-Centered Clinical Research Network (PCORnet). More

Inside The Latest Issue

Groundbreaking therapies on the way for cancer, heart failure Pain management after surgery Drug overview: Dabigatran for DVT, PE

February 17, 2015

IN CASE YOU MISSED IT

Entry-level salaries for hospital pharmacists expected to decline

Pharmacists part of innovative programs to reduce hospital readmissions

High-dose flu vaccine more effective in prevention of influenza hospitalizations in elderly

Continuing education

New and emerging therapies for the treatment of diabetes

MTM opportunities in caring for the patient with cardiovascular disease

MTM essentials for smoking cessation

Get the free app!